SCHEMBL1206189

SCHEMBL1206189

CCCN(CCC)Cc1ccc(NCc2ccc(CN(Cc3ccn[nH]3)Cc3ncc[nH]3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.43
TAAR1 Q96RJ0 3/20 0.38
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
KLK1 P06870 1/20 0.35
KLK5 Q9Y337 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 3/20 0.35
GLA P06280 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MAPT P10636 2/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.32
RORC P51449 2/20 0.32
CDK2 P24941 1/20 0.31
FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205938 0.90 CXCR4 (0.50) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL27630523 0.87 CXCR4 (0.35) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL12894266 0.82 CXCR4 (0.44) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL1206791 0.82 CXCR4 (0.48) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL1206549 0.80 CXCR4 (0.68) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL27630524 0.78 CXCR4 (0.35) CXCR4CYP2D6TSHRSMN1; SMN2LMNA
SCHEMBL1206550 0.77 CXCR4 (0.41) CXCR4TAAR1CYP2D6TSHRKLK1
SCHEMBL1638068 0.73 CXCR4 (0.53) CXCR4TAAR1CYP2D6TSHRSMN1; SMN2
SCHEMBL1638066 0.73 CXCR4 (0.53) CXCR4TAAR1CYP2D6TSHRSMN1; SMN2
SCHEMBL1206233 0.73 CXCR4 (0.55) CXCR4TAAR1CYP2D6TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US claimed
CN-1646495-A Amine compounds and use thereof KUREHA CHEMICAL IND CO LTD (JP) 2005-07-27 CN claimed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP claimed
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-02-24 US disclosed
US-7833991-B2 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2010-11-16 US disclosed
CN-100528846-C Amine compounds and use thereof KUREHA CHEMICAL IND CO LTD (JP) 2009-08-19 CN disclosed
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists KUREHA CORPORATION (JP) 2007-09-06 US disclosed
US-7176227-B2 For example, N-(4-{[bis(1H-imidazol-2-ylmethyl)-amino]-methyl}-benzyl)-N',N'-dipropylbutane-1,4-diamine; efficacious against diseases such as infection with HIV virus, rheumatism, and cancer metastasis KUREHA CORPORATION (JP) 2007-02-13 US disclosed
US-20050165063-A1 Amine compounds and use thereof KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) 2005-07-28 US disclosed
CN-1646495-A Amine compounds and use thereof KUREHA CHEMICAL IND CO LTD (JP) 2005-07-27 CN disclosed
EP-1550657-A1 AMINE COMPOUNDS AND USE THEREOF Kureha Chemical Industry Co., Ltd. (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165063-A1 Amine compounds and use thereof NR0B2, NR5A2, NR1H4 CXCR4 90/4885TAAR1 137/4885CYP2D6 54/4885
US-20110046113-A1 AMINE COMPOUND AND USE THEREOF NR0B2, NR1D2, NR0B1 CXCR4 76/4885TAAR1 66/4885CYP2D6 70/4885
US-20070208033-A1 For use as antimetastatic agent or antiviral agent for HIV infection; N-(4-dipropylaminomethylphenyl)-4-{[(1H-imidazol-2-ylmethyl)-(1-methyl-1H-imidazol-2-ylmethyl)-amino]-methyl}-benzamide; chemokine receptor CXCR4 antagonists CXCR4, CXCR6, CCR5 CXCR4 1/4885TAAR1 588/4885CYP2D6 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.